Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Peter Gale

Leukemia

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Leukemia|January 30, 2019
Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma?Giovanni Barosi, Robert Peter Gale
Leukemia|March 4, 2023
Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectivesGiovanni Barosi, Vittorio Rosti, Robert Peter Gale
Leukemia|June 12, 2021
NK-/T-cell lymphomasHua Wang, Bi-Bo Fu, Robert Peter Gale, et al.
Leukemia|August 20, 2021
Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?Xiao-Shuai Zhang, Robert Peter Gale, Xiao-Jun Huang, et al.
Leukemia|December 5, 2024
Is there really an accelerated phase of chronic myeloid leukaemia at presentation?Sen Yang, Xiaoshuai Zhang, Robert Peter Gale, et al.
Leukemia|January 10, 2020
Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?Elihu Estey, Judith E Karp, Ashkan Emadi, et al.
Leukemia|May 13, 2022
Co-variates associated with outcomes of tyrosine kinase-inhibitor therapy in persons with chronic myeloid leukaemia initially presenting in accelerated phaseSen Yang, Xiao-Shuai Zhang, Robert Peter Gale, et al.
Leukemia|February 23, 2022
A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapyXiao-Shuai Zhang, Robert Peter Gale, Mei-Jie Zhang, et al.
Leukemia|May 7, 2020
Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysisHuan Li, Chongxiang Chen, Fang Hu, et al.
Leukemia|May 15, 2021
JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysisChong-Xiang Chen, Jiao-Jiao Wang, Huan Li, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Leukemia|January 30, 2019
Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma?Giovanni Barosi, Robert Peter Gale
Leukemia|March 4, 2023
Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectivesGiovanni Barosi, Vittorio Rosti, Robert Peter Gale
Leukemia|June 12, 2021
NK-/T-cell lymphomasHua Wang, Bi-Bo Fu, Robert Peter Gale, et al.
Leukemia|August 20, 2021
Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?Xiao-Shuai Zhang, Robert Peter Gale, Xiao-Jun Huang, et al.
Leukemia|December 5, 2024
Is there really an accelerated phase of chronic myeloid leukaemia at presentation?Sen Yang, Xiaoshuai Zhang, Robert Peter Gale, et al.
Leukemia|January 10, 2020
Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?Elihu Estey, Judith E Karp, Ashkan Emadi, et al.
Leukemia|May 13, 2022
Co-variates associated with outcomes of tyrosine kinase-inhibitor therapy in persons with chronic myeloid leukaemia initially presenting in accelerated phaseSen Yang, Xiao-Shuai Zhang, Robert Peter Gale, et al.
Leukemia|February 23, 2022
A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapyXiao-Shuai Zhang, Robert Peter Gale, Mei-Jie Zhang, et al.
Leukemia|May 7, 2020
Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysisHuan Li, Chongxiang Chen, Fang Hu, et al.
Leukemia|May 15, 2021
JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysisChong-Xiang Chen, Jiao-Jiao Wang, Huan Li, et al.
Pageof 4